M. F. Beketova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
M. F. Beketova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana Valentinovna Beketova
V.A. Nasonova Research Institute of Rheumatology; Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation; Moscow Polytechnic University
5 shared publications - Evgeniy S. Fedorov
V.A. Nasonova Research Institute of Rheumatology
4 shared publications - Svetlana Olegovna Salugina
V.A. Nasonova Research Institute of Rheumatology
4 shared publications - V. V. Babak
V.A. Nasonova Research Institute of Rheumatology
4 shared publications - Anna Vasilievna Torgashina
V.A. Nasonova Research Institute of Rheumatology
3 shared publications - N. O. Levina
Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation
3 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (1) , 5-11
The problems of undifferentiated autoinflammatory diseases
Despite the progress of molecular genetic testing, the diagnostic issues of monogenic autoinflammatory diseases (AIDs) remain largely unresolved. It’s associated with a heterogeneous clinical picture and problems in interpreting the results of molecular genetic testing. A significant group of patients are classified as recently identified undifferentiated AIDs, which characterized by the presence of clinical signs of monogenic AIDs and negative or inconclusive result of molecular genetic testing. In recent years, the problem of undifferentiated AIDs or SURF (syndrome of undefined recurrent fevers) has been considered within the framework of the concept of genetically transitional disease. It was discussed that undifferentiated AIDs with genetic variants of uncertain significance should be distinguished into a special subtype. Further study of such cohorts is needed to identify significant biomarkers and find therapeutic targets.
- 2 March 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (1) , 5-11
Open AccessThe problems of undifferentiated autoinflammatory diseases
Despite the progress of molecular genetic testing, the diagnostic issues of monogenic autoinflammatory diseases (AIDs) remain largely unresolved. It’s associated with a heterogeneous clinical picture and problems in interpreting the results of molecular genetic testing. A significant group of patients are classified as recently identified undifferentiated AIDs, which characterized by the presence of clinical signs of monogenic AIDs and negative or inconclusive result of molecular genetic testing. In recent years, the problem of undifferentiated AIDs or SURF (syndrome of undefined recurrent fevers) has been considered within the framework of the concept of genetically transitional disease. It was discussed that undifferentiated AIDs with genetic variants of uncertain significance should be distinguished into a special subtype. Further study of such cohorts is needed to identify significant biomarkers and find therapeutic targets.
- Open Access
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 63-70
Results of molecular genetic testing in 115 patients with suspected monogenic autoinflammatory disease
In the last decade, an interest has increased in autoinflammatory diseases (AIDs) associated with a mutation in a specific gene, while the pathogenetic significance of the identified genetic variants continues to be clarified. Objective: to study the frequency and spectrum of genetic variants identified by molecular genetic testing (MGT) and the clinical features in patients with suspected monogenic AIDs (mAIDs). Material and methods. MGT of target genes was performed in 115 patients with suspected mAIDs (median age 10 [5; 14] years; male-to-female ratio 1:1.1) using massively parallel sequencing (in 89% of cases, a 65-gene panel was used). Results and discussion. The patients were divided into two groups. Group 1 included 44 (38%) patients with identified genetic variants, and Group 2 included 71 patients with genetically negative MGT results. Thirty-six monogenic variants were identified (11 in the MEFV gene, 5 in NOD2, 4 in NLRP3, 3 in TNFRSF1A, 2 each in MVK, RAG1, NLRP1, ADA2, and 1 each in IFIH1, NLRP12, UNC13D, RIPK1, IL36RN), as well as 8 digenic/oligogenic combinations (2 in MEFV/TNFRSF1A; 1 each in MEFV/MVK/TNFAIP3, MEFV/NOD2/PSTPIP1, NOD2/MEFV, IL36RN/STX11, MEFV/NLRP12, SH2D1A/TNFAIP3). In both groups, the most common were: fever (in 89% and 88% of cases), skin involvement (59% and 47%), arthralgia (61% and 45%), arthritis (36% and 25%), gastrointestinal symptoms (34% and 37%), and lymphadenopathy (28% and 35%), hyperproduction of autoantibodies was detected in 15% and 27% of cases, respectively. Differences between the groups for these parameters were not statistically significant. Chest pain was observed significantly more often in Group 1 than in Group 2 (14% vs 1%, respectively; p=0.008). Conclusion. MGT identified mutations in 38% of patients with suspected mAIDs. Genetic variants from the group of major monogenic AIDs (FMF, TRAPS, CAPS, HIDS/MKD) were most common. When clinical and laboratory data were compared between the groups with positive and negative MGT results, no substantial differences were found. Patients with negative MGT results who meet AIDs criteria require extended evaluation, including whole-exome/whole-genome sequencing.
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 63-70
Open AccessResults of molecular genetic testing in 115 patients with suspected monogenic autoinflammatory disease
In the last decade, an interest has increased in autoinflammatory diseases (AIDs) associated with a mutation in a specific gene, while the pathogenetic significance of the identified genetic variants continues to be clarified. Objective: to study the frequency and spectrum of genetic variants identified by molecular genetic testing (MGT) and the clinical features in patients with suspected monogenic AIDs (mAIDs). Material and methods. MGT of target genes was performed in 115 patients with suspected mAIDs (median age 10 [5; 14] years; male-to-female ratio 1:1.1) using massively parallel sequencing (in 89% of cases, a 65-gene panel was used). Results and discussion. The patients were divided into two groups. Group 1 included 44 (38%) patients with identified genetic variants, and Group 2 included 71 patients with genetically negative MGT results. Thirty-six monogenic variants were identified (11 in the MEFV gene, 5 in NOD2, 4 in NLRP3, 3 in TNFRSF1A, 2 each in MVK, RAG1, NLRP1, ADA2, and 1 each in IFIH1, NLRP12, UNC13D, RIPK1, IL36RN), as well as 8 digenic/oligogenic combinations (2 in MEFV/TNFRSF1A; 1 each in MEFV/MVK/TNFAIP3, MEFV/NOD2/PSTPIP1, NOD2/MEFV, IL36RN/STX11, MEFV/NLRP12, SH2D1A/TNFAIP3). In both groups, the most common were: fever (in 89% and 88% of cases), skin involvement (59% and 47%), arthralgia (61% and 45%), arthritis (36% and 25%), gastrointestinal symptoms (34% and 37%), and lymphadenopathy (28% and 35%), hyperproduction of autoantibodies was detected in 15% and 27% of cases, respectively. Differences between the groups for these parameters were not statistically significant. Chest pain was observed significantly more often in Group 1 than in Group 2 (14% vs 1%, respectively; p=0.008). Conclusion. MGT identified mutations in 38% of patients with suspected mAIDs. Genetic variants from the group of major monogenic AIDs (FMF, TRAPS, CAPS, HIDS/MKD) were most common. When clinical and laboratory data were compared between the groups with positive and negative MGT results, no substantial differences were found. Patients with negative MGT results who meet AIDs criteria require extended evaluation, including whole-exome/whole-genome sequencing.
- Open Access
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 113-118
Skin involvement in rare monogenic autoinflammatory diseases. Part 2
Autoinflammatory diseases (AIDs) represent a heterogeneous group of conditions pathogenetically associated with dysregulation of the innate immune system and clinically characterized by recurrent episodes of sterile inflammation in the affected organs in the absence of infection, allergy, and high titers of circulating autoantibodies or autoreactive T cells. The spectrum of genetically determined AIDs is quite diverse and continues to expand. Cutaneous manifestations are among the key components of AIDs and often serve as an important clue to diagnosis. This applies both to the classical, most extensively studied monogenic AIDs (mAIDs) and to more rare and less familiar forms of AIDs.Part 1 of the article presented the characteristics of skin manifestations in classical mAIDs (Familial Mediterranean Fever, FMF; Cryopyrin-Associated Periodic Syndromes, CAPS; Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, TRAPS; Hyper-IgD Syndrome / Mevalonate Kinase Deficiency, HIDS/MKD). Part 2 focuses on patterns of skin involvement in more rare mAIDs, whose pathogenesis is based not only on interleukin-1 activation but also on alternative disease mechanisms, including activation of interferon signaling pathways (interferonopathies) and neutrophilic dermatoses. Diagnostic assessment is greatly facilitated not only by knowledge and correct interpretation of specific cutaneous manifestations in AIDs but also by consideration of characteristic histological markers identified through pathology examination of the skin. Close collaboration between rheumatologists and dermatologists enables timely diagnosis and initiation of targeted therapy.
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 113-118
Open AccessSkin involvement in rare monogenic autoinflammatory diseases. Part 2
Autoinflammatory diseases (AIDs) represent a heterogeneous group of conditions pathogenetically associated with dysregulation of the innate immune system and clinically characterized by recurrent episodes of sterile inflammation in the affected organs in the absence of infection, allergy, and high titers of circulating autoantibodies or autoreactive T cells. The spectrum of genetically determined AIDs is quite diverse and continues to expand. Cutaneous manifestations are among the key components of AIDs and often serve as an important clue to diagnosis. This applies both to the classical, most extensively studied monogenic AIDs (mAIDs) and to more rare and less familiar forms of AIDs.Part 1 of the article presented the characteristics of skin manifestations in classical mAIDs (Familial Mediterranean Fever, FMF; Cryopyrin-Associated Periodic Syndromes, CAPS; Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, TRAPS; Hyper-IgD Syndrome / Mevalonate Kinase Deficiency, HIDS/MKD). Part 2 focuses on patterns of skin involvement in more rare mAIDs, whose pathogenesis is based not only on interleukin-1 activation but also on alternative disease mechanisms, including activation of interferon signaling pathways (interferonopathies) and neutrophilic dermatoses. Diagnostic assessment is greatly facilitated not only by knowledge and correct interpretation of specific cutaneous manifestations in AIDs but also by consideration of characteristic histological markers identified through pathology examination of the skin. Close collaboration between rheumatologists and dermatologists enables timely diagnosis and initiation of targeted therapy.
- Open Access
- 22 December 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (6) , 109-116
Skin involvement in classic monogenic autoinflammatory diseases. Part 1
Autoinflammatory diseases (AIDs) represent a heterogeneous group of conditions pathogenetically associated with dysregulation of innate immunity and clinically characterized by recurrent episodes of sterile inflammation in affected organs in the absence of infection, allergy, and high titers of circulating autoantibodies or autoreactive T cells. The overwhelming majority of monogenic AIDs (mAIDs) are accompanied by skin rashes, the type of which is determined by the specific disease and, to some extent, by differing pathogenetic mechanisms. The first part of the article presents the cutaneous characteristics of the most common mAIDs: Familial Mediterranean fever (FMF), cryopyrinassociated periodic syndromes (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), periodic syndrome with hyperimmunoglobulinemia D / mevalonate kinase deficiency (HIDS/MKD). Skin involvement in these diseases reflects systemic inflammation associated with hyperproduction of the key pro-inflammatory cytokine interleukin (IL)-1β. In other AIDs, symptoms mainly depend on increased levels of cytokines such as IL-18, IL-36, etc. (NLRC4-associated autoinflammatory disease; deficiency of the IL-36 receptor antagonist – DITRA), as well as activation of interferon signaling pathways (interferonopathies). Different pathogenetic mechanisms determine the diversity of clinical phenotypes, including cutaneous manifestations. Knowledge of these features helps establishing a correct diagnosis, obtaining genetic confirmation (without which accurate identification of these rare conditions is impossible today) and selecting appropriate therapy. Pathological examination plays a special auxiliary role and should be used in diagnostically challenging situations.
- 22 December 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (6) , 109-116
Open AccessSkin involvement in classic monogenic autoinflammatory diseases. Part 1
Autoinflammatory diseases (AIDs) represent a heterogeneous group of conditions pathogenetically associated with dysregulation of innate immunity and clinically characterized by recurrent episodes of sterile inflammation in affected organs in the absence of infection, allergy, and high titers of circulating autoantibodies or autoreactive T cells. The overwhelming majority of monogenic AIDs (mAIDs) are accompanied by skin rashes, the type of which is determined by the specific disease and, to some extent, by differing pathogenetic mechanisms. The first part of the article presents the cutaneous characteristics of the most common mAIDs: Familial Mediterranean fever (FMF), cryopyrinassociated periodic syndromes (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), periodic syndrome with hyperimmunoglobulinemia D / mevalonate kinase deficiency (HIDS/MKD). Skin involvement in these diseases reflects systemic inflammation associated with hyperproduction of the key pro-inflammatory cytokine interleukin (IL)-1β. In other AIDs, symptoms mainly depend on increased levels of cytokines such as IL-18, IL-36, etc. (NLRC4-associated autoinflammatory disease; deficiency of the IL-36 receptor antagonist – DITRA), as well as activation of interferon signaling pathways (interferonopathies). Different pathogenetic mechanisms determine the diversity of clinical phenotypes, including cutaneous manifestations. Knowledge of these features helps establishing a correct diagnosis, obtaining genetic confirmation (without which accurate identification of these rare conditions is impossible today) and selecting appropriate therapy. Pathological examination plays a special auxiliary role and should be used in diagnostically challenging situations.
- Open Access
- 31 October 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (5) , 465-473
Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results
Patients with ANCA-associated systemic vasculitis (AAV) are at risk of severe COVID-19. At the same time, in immunocompromised patients, in particular those receiving anti-B cell therapy with rituximab (RTX), the post-vaccination effect may be insufficient. Since 2022 the long-acting virus-neutralizing monoclonal antibodies (MAB) tixagevimab and cilgavimab (Evushheld, AZD7442) have been used as pre-exposure prophylaxis for COVID-19.The aim of the study is to evaluate the effectiveness of tixagevimab and cilgavimab (TC) for pre-exposure prophylaxis of COVID-19 and its safety in RTX treated patients with AAV.Materials and methods. The prospective study included 63 patients with AAV receiving RTX. Median age 53 (19– 79) years, M:F 1:1.1. From March 2022 to June 2023, TC was administered in a total dose of 300 mg and/or 600 mg. Observation continued until April 2024. In November 2023 and in April 2024 a telephone and/or online survey was conducted simultaneously to identify confirmed cases of COVID-19 and adverse reactions. The survey also included the Treatment Satisfaction Questionnaire version 9 (TSQM-9). Considering the duration of the TC effect (6 months), COVID-19 cases were divided into two groups depending on the interval after the last administration of the TC: up to 6 months inclusive – group 1; more than 6 months – group 2.Results. During the two-year follow-up period, confirmed COVID-19 was detected in 31.7% patients, the median interval between the last TC administration and the development of COVID-19 was 5.5 [2–19] months. In group 1, which included 12 cases of COVID-19, 92% of patients had a mild form of the disease, only one had lung damage, and there were no fatal outcomes. In group 2, COVID-19, detected after the cessation of the TC effect in 9 patients, was accompanied by lung damage in 89% of cases, required hospitalization in 78%, and fatal in two patients. Four patients had a prolonged course of severe COVID-19 with persistence of SARS-CoV-2 (pCOVID, persistent COVID). In 4 cases, including 3 cases with pCOVID, treatment was carried out with the combined antiviral drug nirmarelvir + ritonavir (Skyvira) in combination with intravenous human immunoglobulin (IVIG) with effect. There were no statistically significant differences in the incidence of COVID-19 in patients with secondary immunodeficiency and without it (p=0.868). At the final stage of the study, the serum level of IgG antibodies to SARS-CoV-2 was examined in 34 patients, its median was 70.4 (0.33–1086.1) binding antibody units (BAU), which indicates a lack of neutralizing antibodies in most patients; there were no statistical differences in their level between patients with and without COVID-19 (p=0.685). No adverse reactions directly related to the use of TC were observed. A high level of the TSQM-9 global treatment satisfaction domain was noted with a median 71.4 (14.3–100); 72,4% of respondents answered “satisfied”– “extremely satisfied” to the first question of TSQM-9 (effectiveness domain).Conclusions. Pre-exposure prophylaxis of COVID-19 using TC in patients with AAV receiving RTM was safe and allowed to reduce the risk of severe COVID-19 and avoid deaths during the period of TC action. After the cessation of TC, an increase in the frequency of severe COVID-19 with the need for hospitalization and deaths was observed, cases of pCOVID were noted. The use of a combination of Skyvira and IVIG for the treatment of pCOVID was effective in all cases. The use of MAB for pre-exposure prophylaxis of COVID-19 in patients with AAV and other rheumatic diseases requires further in-depth study.
- 31 October 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (5) , 465-473
Open AccessPre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results
Patients with ANCA-associated systemic vasculitis (AAV) are at risk of severe COVID-19. At the same time, in immunocompromised patients, in particular those receiving anti-B cell therapy with rituximab (RTX), the post-vaccination effect may be insufficient. Since 2022 the long-acting virus-neutralizing monoclonal antibodies (MAB) tixagevimab and cilgavimab (Evushheld, AZD7442) have been used as pre-exposure prophylaxis for COVID-19.The aim of the study is to evaluate the effectiveness of tixagevimab and cilgavimab (TC) for pre-exposure prophylaxis of COVID-19 and its safety in RTX treated patients with AAV.Materials and methods. The prospective study included 63 patients with AAV receiving RTX. Median age 53 (19– 79) years, M:F 1:1.1. From March 2022 to June 2023, TC was administered in a total dose of 300 mg and/or 600 mg. Observation continued until April 2024. In November 2023 and in April 2024 a telephone and/or online survey was conducted simultaneously to identify confirmed cases of COVID-19 and adverse reactions. The survey also included the Treatment Satisfaction Questionnaire version 9 (TSQM-9). Considering the duration of the TC effect (6 months), COVID-19 cases were divided into two groups depending on the interval after the last administration of the TC: up to 6 months inclusive – group 1; more than 6 months – group 2.Results. During the two-year follow-up period, confirmed COVID-19 was detected in 31.7% patients, the median interval between the last TC administration and the development of COVID-19 was 5.5 [2–19] months. In group 1, which included 12 cases of COVID-19, 92% of patients had a mild form of the disease, only one had lung damage, and there were no fatal outcomes. In group 2, COVID-19, detected after the cessation of the TC effect in 9 patients, was accompanied by lung damage in 89% of cases, required hospitalization in 78%, and fatal in two patients. Four patients had a prolonged course of severe COVID-19 with persistence of SARS-CoV-2 (pCOVID, persistent COVID). In 4 cases, including 3 cases with pCOVID, treatment was carried out with the combined antiviral drug nirmarelvir + ritonavir (Skyvira) in combination with intravenous human immunoglobulin (IVIG) with effect. There were no statistically significant differences in the incidence of COVID-19 in patients with secondary immunodeficiency and without it (p=0.868). At the final stage of the study, the serum level of IgG antibodies to SARS-CoV-2 was examined in 34 patients, its median was 70.4 (0.33–1086.1) binding antibody units (BAU), which indicates a lack of neutralizing antibodies in most patients; there were no statistical differences in their level between patients with and without COVID-19 (p=0.685). No adverse reactions directly related to the use of TC were observed. A high level of the TSQM-9 global treatment satisfaction domain was noted with a median 71.4 (14.3–100); 72,4% of respondents answered “satisfied”– “extremely satisfied” to the first question of TSQM-9 (effectiveness domain).Conclusions. Pre-exposure prophylaxis of COVID-19 using TC in patients with AAV receiving RTM was safe and allowed to reduce the risk of severe COVID-19 and avoid deaths during the period of TC action. After the cessation of TC, an increase in the frequency of severe COVID-19 with the need for hospitalization and deaths was observed, cases of pCOVID were noted. The use of a combination of Skyvira and IVIG for the treatment of pCOVID was effective in all cases. The use of MAB for pre-exposure prophylaxis of COVID-19 in patients with AAV and other rheumatic diseases requires further in-depth study.
- Open Access
- 31 August 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (4) , 458-465
Monogenic autoinflammatory syndromes with features of systemic vasculitis: a new field of rheumatology
The article is dedicated to a new actual problem in rheumatology: vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes in adult. The features of the clinical course of the rarely diagnosed VEXAS syndrome, as well as the SAVI and COPA syndromes, which sometimes occur in adults, are considered. Promising directions of future treatment are discussed.
- 31 August 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (4) , 458-465
Open AccessMonogenic autoinflammatory syndromes with features of systemic vasculitis: a new field of rheumatology
The article is dedicated to a new actual problem in rheumatology: vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes in adult. The features of the clinical course of the rarely diagnosed VEXAS syndrome, as well as the SAVI and COPA syndromes, which sometimes occur in adults, are considered. Promising directions of future treatment are discussed.
- Open Access
- 28 April 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (2) , 158-164
Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
The problem of prevention of coronavirus disease 2019 (COVID-19) in patients with immune-mediated inflammatory rheumatic diseases (IMRD) remains highly relevant. The presence of IRD is associated with a high risk of disease and severe course of COVID-19 during immunosuppressive treatment, primarily anti-B cell therapy with rituximab (RTX), and a low level of post-vaccination response in such patients. A new strategy for the prevention and treatment of COVID-19 are virus-neutralizing monoclonal antibodies to coronavirus; currently, combined long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld) are registered for prevention in the world and the Russian Federation. . Tixagevimab and cilgavimab (TC) show neutralizing activity against SARS-CoV-2, including the Omicron strain, primarily its variants BA.4, BA.5, BA.2.75 ("Centaur").Objective – to evaluate the efficacy and safety of TC for pre-exposure prophylaxis of COVID-19 in rheumatic patients receiving RTX, based on a prospective observational study.Materials and methods. The main group included 86 patients with various IMRD receiving RTX: 50 of them had ANCA-associated systemic vasculitis (AAV), 15 – rheumatoid arthritis, 9 – Sjogren’s syndrome (SS), 4 – IgG4-related disease, 3 – systemic lupus erythematosus (SLE), 3 – dermatomyositis (DM), 2 – systemic scleroderma (SSD). Median age was 59 (19–82) years; male : female ratio – 1:1,8. From March 26 to August 30 2022, patients received a single intramuscular injection of TC in a total dose of 300 mg, mainly after RTX (in 52% of cases, in 28% on the next day after RTX). The control group included 42 patients with AAV (median age – 45 (35–71) years; male : female ratio – 1:1), also treated with RTX, who did not receive pre-exposure prophylaxis of TC. The duration of observation was 7 months, until November 1 2022. At this time, 98% of confirmed cases of coronavirus in the Russian Federation were Omicron. A telephone and/or online survey of patient has been conducted to detect cases of COVID-19 and adverse reactions.Results. In the TC group, confirmed coronavirus infection have been detected in 17 (20%) patients (AAV – 10, SS – 3, SSD – 2, SLE – 1, DM – 1), with fever in 7 (8%), only in one case hospitalization was required (lung damage was not detected in computed tomography), in two cases, according to CT mild lung damage (CT 1–2), there were no deaths. Good TC’s tolerability was noted, signs not associated with COVID-19 or progression of IMRD after administration of TC were observed in 8 (9%) patients (GPA – 3 MPA – 1, RA – 2, SLE – 1, IgG4-related disease – 1), adverse reactions definitely associated with the use of TC were not found. The most serious event not associated with coronavirus infection was the progression of polyneuropathy in a patient with RA. In the control group, 3 (7%) patients were diagnosed with COVID-19, one with severe lung injury (CT 3, pulmonary embolism) and death.Conclusions. The data of clinical studies and our own clinical experience evidence the effectiveness of the use of a combination of long-acting monoclonal antibodies TC (Evusheld), registered for indications for pre-exposure prophylaxis and treatment of COVID-19. Patients with IMRD treated with RTX have a favorable safety profile of TC. The introduction of virus-neutralizing monoclonal antibodies, a new drug class for the prevention and treatment of infectious diseases, opens significant prospects for improving the prognosis of patients with IRD.
- 28 April 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (2) , 158-164
Open AccessExperience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
The problem of prevention of coronavirus disease 2019 (COVID-19) in patients with immune-mediated inflammatory rheumatic diseases (IMRD) remains highly relevant. The presence of IRD is associated with a high risk of disease and severe course of COVID-19 during immunosuppressive treatment, primarily anti-B cell therapy with rituximab (RTX), and a low level of post-vaccination response in such patients. A new strategy for the prevention and treatment of COVID-19 are virus-neutralizing monoclonal antibodies to coronavirus; currently, combined long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld) are registered for prevention in the world and the Russian Federation. . Tixagevimab and cilgavimab (TC) show neutralizing activity against SARS-CoV-2, including the Omicron strain, primarily its variants BA.4, BA.5, BA.2.75 ("Centaur").Objective – to evaluate the efficacy and safety of TC for pre-exposure prophylaxis of COVID-19 in rheumatic patients receiving RTX, based on a prospective observational study.Materials and methods. The main group included 86 patients with various IMRD receiving RTX: 50 of them had ANCA-associated systemic vasculitis (AAV), 15 – rheumatoid arthritis, 9 – Sjogren’s syndrome (SS), 4 – IgG4-related disease, 3 – systemic lupus erythematosus (SLE), 3 – dermatomyositis (DM), 2 – systemic scleroderma (SSD). Median age was 59 (19–82) years; male : female ratio – 1:1,8. From March 26 to August 30 2022, patients received a single intramuscular injection of TC in a total dose of 300 mg, mainly after RTX (in 52% of cases, in 28% on the next day after RTX). The control group included 42 patients with AAV (median age – 45 (35–71) years; male : female ratio – 1:1), also treated with RTX, who did not receive pre-exposure prophylaxis of TC. The duration of observation was 7 months, until November 1 2022. At this time, 98% of confirmed cases of coronavirus in the Russian Federation were Omicron. A telephone and/or online survey of patient has been conducted to detect cases of COVID-19 and adverse reactions.Results. In the TC group, confirmed coronavirus infection have been detected in 17 (20%) patients (AAV – 10, SS – 3, SSD – 2, SLE – 1, DM – 1), with fever in 7 (8%), only in one case hospitalization was required (lung damage was not detected in computed tomography), in two cases, according to CT mild lung damage (CT 1–2), there were no deaths. Good TC’s tolerability was noted, signs not associated with COVID-19 or progression of IMRD after administration of TC were observed in 8 (9%) patients (GPA – 3 MPA – 1, RA – 2, SLE – 1, IgG4-related disease – 1), adverse reactions definitely associated with the use of TC were not found. The most serious event not associated with coronavirus infection was the progression of polyneuropathy in a patient with RA. In the control group, 3 (7%) patients were diagnosed with COVID-19, one with severe lung injury (CT 3, pulmonary embolism) and death.Conclusions. The data of clinical studies and our own clinical experience evidence the effectiveness of the use of a combination of long-acting monoclonal antibodies TC (Evusheld), registered for indications for pre-exposure prophylaxis and treatment of COVID-19. Patients with IMRD treated with RTX have a favorable safety profile of TC. The introduction of virus-neutralizing monoclonal antibodies, a new drug class for the prevention and treatment of infectious diseases, opens significant prospects for improving the prognosis of patients with IRD.
- Open Access
- 6 September 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (4) , 420-426
Avascular necrosis as a part of post-COVID syndrome. Case reports
Coronavirus disease 2019 (COVID-19) can manifest with a wide range of extrapulmonary symptoms and have longterm consequences (so-called post-covid syndrome (PCS) or “long COVID-19”). Manifestations of PCS show a wide clinical spectrum and include cardiac, pulmonary, neurological, gastrointestinal, dermatological, mental symptoms, vascular thrombosis and avascular necrosis (AVN) of the bones.We present our own observations of the development of bone’s AVN in 3 patients who underwent COVID-19 with bilateral lung disease, in whom after 4–6 months the first signs of AVN were noted and characterized by a progressive multifocal lesion, which was accompanied by an increase of C-reactive protein concentration.The pathogenetic mechanisms of AVN development in the framework of PCS are discussed. The importance of conservative and surgical methods in the treatment of the disease are considered. Since the development of AVN of various localizations with a long latent period is possible after COVID-19, long-term monitoring of patients is required. Further study of the problem of PCS in general and AVN in particular is required.
- 6 September 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (4) , 420-426
Open AccessAvascular necrosis as a part of post-COVID syndrome. Case reports
Coronavirus disease 2019 (COVID-19) can manifest with a wide range of extrapulmonary symptoms and have longterm consequences (so-called post-covid syndrome (PCS) or “long COVID-19”). Manifestations of PCS show a wide clinical spectrum and include cardiac, pulmonary, neurological, gastrointestinal, dermatological, mental symptoms, vascular thrombosis and avascular necrosis (AVN) of the bones.We present our own observations of the development of bone’s AVN in 3 patients who underwent COVID-19 with bilateral lung disease, in whom after 4–6 months the first signs of AVN were noted and characterized by a progressive multifocal lesion, which was accompanied by an increase of C-reactive protein concentration.The pathogenetic mechanisms of AVN development in the framework of PCS are discussed. The importance of conservative and surgical methods in the treatment of the disease are considered. Since the development of AVN of various localizations with a long latent period is possible after COVID-19, long-term monitoring of patients is required. Further study of the problem of PCS in general and AVN in particular is required.
- Open Access
- 14 May 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (2) , 162-164
On the issue of post COVID-19 condition in patients with rheumatic diseases
Actual problems of rheumatology include the possibility of developing a wide range of long-term consequences of COVID-19, so-called post-COVID syndrome (PCS). The results of our own research are presented, during which among 45 patients over 18 years with rheumatic diseases (RD) PCS was detected in 20% cases: 6 of them had ANCAassociated vasculitis (AAV) and one each for rheumatoid arthritis, juvenile arthritis and osteoarthritis. In AAV cases PCS was more severe and varied than in other RD: lung lesions according to computed tomography (up to the damage 75% of the lung parenchyma), skin an d nervous (Guillain–Barré syndrome) lesions, myalgias, arthralgias were present. In most patients PCS ended in recovery, sudden death occurred only in the patient with AAV. The frequency of RD’s relapses in patients with PCS was 9%. Relapses were not noted in AAV, against the background of anti-B cell therapy with rituximab. Our own results and literature data indicate that patients with RD after COVID-19 need careful continuous monitoring to detect long-term complications of coronavirus infection and early diagnosis of relapses of the underlying disease.
- 14 May 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (2) , 162-164
Open AccessOn the issue of post COVID-19 condition in patients with rheumatic diseases
Actual problems of rheumatology include the possibility of developing a wide range of long-term consequences of COVID-19, so-called post-COVID syndrome (PCS). The results of our own research are presented, during which among 45 patients over 18 years with rheumatic diseases (RD) PCS was detected in 20% cases: 6 of them had ANCAassociated vasculitis (AAV) and one each for rheumatoid arthritis, juvenile arthritis and osteoarthritis. In AAV cases PCS was more severe and varied than in other RD: lung lesions according to computed tomography (up to the damage 75% of the lung parenchyma), skin an d nervous (Guillain–Barré syndrome) lesions, myalgias, arthralgias were present. In most patients PCS ended in recovery, sudden death occurred only in the patient with AAV. The frequency of RD’s relapses in patients with PCS was 9%. Relapses were not noted in AAV, against the background of anti-B cell therapy with rituximab. Our own results and literature data indicate that patients with RD after COVID-19 need careful continuous monitoring to detect long-term complications of coronavirus infection and early diagnosis of relapses of the underlying disease.